ArTS Archivio della ricerca di Trieste

BERGAMO, ALBERTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.833
AS - Asia 4.870
EU - Europa 4.530
SA - Sud America 703
AF - Africa 115
Continente sconosciuto - Info sul continente non disponibili 14
OC - Oceania 12
Totale 20.077
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.705
SG - Singapore 1.874
CN - Cina 1.142
PL - Polonia 776
IT - Italia 673
UA - Ucraina 628
SE - Svezia 587
BR - Brasile 536
HK - Hong Kong 499
VN - Vietnam 499
DE - Germania 379
KR - Corea 269
GB - Regno Unito 262
FI - Finlandia 255
FR - Francia 252
RU - Federazione Russa 240
TR - Turchia 156
BG - Bulgaria 145
IE - Irlanda 128
BD - Bangladesh 121
IN - India 79
AR - Argentina 72
NL - Olanda 57
CA - Canada 55
MX - Messico 42
CH - Svizzera 32
IQ - Iraq 30
JP - Giappone 27
ES - Italia 24
ZA - Sudafrica 24
EC - Ecuador 23
MA - Marocco 23
ID - Indonesia 22
CO - Colombia 20
PY - Paraguay 19
SA - Arabia Saudita 19
AT - Austria 17
BE - Belgio 15
UZ - Uzbekistan 15
PH - Filippine 14
EU - Europa 13
KE - Kenya 13
PK - Pakistan 12
VE - Venezuela 12
SN - Senegal 11
TW - Taiwan 11
RO - Romania 10
AU - Australia 9
CL - Cile 9
JO - Giordania 9
TH - Thailandia 9
DZ - Algeria 8
EG - Egitto 8
KZ - Kazakistan 8
MY - Malesia 8
GR - Grecia 6
HU - Ungheria 6
IL - Israele 6
RS - Serbia 6
TN - Tunisia 6
AE - Emirati Arabi Uniti 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
NG - Nigeria 5
NP - Nepal 5
PT - Portogallo 5
QA - Qatar 5
UY - Uruguay 5
AL - Albania 4
CZ - Repubblica Ceca 4
HN - Honduras 4
IR - Iran 4
JM - Giamaica 4
KW - Kuwait 4
PE - Perù 4
BW - Botswana 3
CI - Costa d'Avorio 3
DK - Danimarca 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
SK - Slovacchia (Repubblica Slovacca) 3
BB - Barbados 2
BO - Bolivia 2
BY - Bielorussia 2
CR - Costa Rica 2
GA - Gabon 2
GE - Georgia 2
GT - Guatemala 2
HR - Croazia 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LT - Lituania 2
MN - Mongolia 2
NI - Nicaragua 2
PA - Panama 2
PR - Porto Rico 2
SV - El Salvador 2
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
Totale 20.056
Salva come PNG Salva come JPEG
Città #
Singapore 1.164
Ann Arbor 857
Ashburn 841
Fairfield 793
Woodbridge 753
Houston 660
Warsaw 641
Jacksonville 567
San Jose 539
Chandler 511
Hong Kong 485
Wilmington 461
Seattle 334
Hefei 309
Beijing 271
Cambridge 268
Seoul 265
Princeton 247
Santa Clara 224
Boardman 197
Ho Chi Minh City 170
Chicago 160
Sofia 142
Los Angeles 138
Trieste 133
Dublin 125
Izmir 123
Zgierz 122
Columbus 118
Hanoi 118
Lauterbourg 110
Milan 102
Dearborn 94
Dallas 92
Buffalo 85
Moscow 82
The Dalles 75
San Diego 62
Council Bluffs 47
Helsinki 47
São Paulo 43
Frankfurt am Main 41
Munich 41
New York 40
London 37
Phoenix 31
Düsseldorf 29
Verona 27
Bern 26
Redwood City 25
Falls Church 22
Miano 22
Orem 22
Turku 22
Atlanta 21
Des Moines 21
Guangzhou 21
Nanjing 21
Tokyo 20
Da Nang 18
Norwalk 17
Denver 16
Rio de Janeiro 16
Chennai 15
Mexico City 15
Poplar 15
San Francisco 15
Shanghai 15
Brussels 14
Kunming 14
Montreal 14
Tianjin 14
Toronto 14
North Bergen 13
Biên Hòa 12
Casablanca 12
Haiphong 12
Hangzhou 12
Rome 12
Tashkent 12
Belo Horizonte 11
Dakar 11
Johannesburg 11
Nairobi 11
Redmond 11
Vienna 11
Zhengzhou 11
Amsterdam 10
Andover 10
Costa Mesa 10
Curitiba 10
Dhaka 10
Dong Ket 10
Jinan 10
Auburn Hills 9
Boston 9
Brasília 9
Brooklyn 9
Hải Dương 9
Nuremberg 9
Totale 13.562
Salva come PNG Salva come JPEG
Nome #
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 408
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 371
Chemical and Molecular Approach to Tumor Metastases 349
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 292
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 256
Long non-coding RNA gas5 and intestinal mmp2 and mmp9 expression: A translational study in pediatric patients with IBD 255
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 249
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 240
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 234
Antimetastatic action and lymphocyte activation by the modified lysozyme mPEG-Lyso in mice with MCa mammary carcinoma 223
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 223
Phototoxic Activity and DNA Interactions of Water-Soluble Porphyrins and Their Rhenium(I) Conjugates 221
Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen 219
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 219
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 215
Complessi di Rutenio con elevata attività antitumorale 212
New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity. 212
Age Dependent Modification of the Metabolic Profile of the Tibialis Anterior Muscle Fibers in C57BL/6J Mice 211
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 208
Is the aromatic fragment of piano-stool ruthenium compounds an essential feature for anticancer activity? The development of new Ru(II)-[9]aneS3 analogues. 207
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 207
Antimetastatic properties and DNA interactions of the novel class of dimeric Ru(III) compounds Na2[{trans-RuCl4(Me2SO)}2(μ-L)] (L=ditopic, non-chelating aromatic N-ligand). A preliminary investigation 205
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 202
Ruthenium complexes can target determinants of tumour malignancy 200
Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A 200
Influence of chemical stability on the activity of the antimetastasis ruthenium compound NAMI-A 197
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 197
Half-sandwich RuIIsingle bond[9]aneS3 complexes structurally similar to antitumor-active organometallic piano-stool compounds: Preparation, structural characterization and in vitro cytotoxic activity 196
Metal-based antitumour drugs in the post-genomic era: what comes next? 196
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 195
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 194
Approaching tumour therapy beyond platinum drugs. Status of the art and perspectives of ruthenium drug candidates. 194
New half sandwich Ru(II) coordination compounds for anticancer activity 194
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenanthrolines and acyclovir or penciclovir 193
Towards Matched Pairs of Porphyrin-ReI/99mTcIConjugates that Combine Photodynamic Activity with Fluorescence and Radio Imaging 191
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 189
Long-term resveratrol treatment improves the capillarization in the skeletal muscles of ageing C57BL/6J mice 188
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 187
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 186
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 186
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 185
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 185
Cardiovascular, neurological, and pulmonary events following vaccination with the BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: An analysis of European data 185
Stimulation of GALT and Activation of Mesenteric Lymphonode Lymphocytes by a Modifìed Iysozyme in CBA Mice with Mca mammary carcinoma 184
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 182
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 181
Ruthenium antimetastatic agents 179
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 177
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 177
Modulation of Activity of Known Cytotoxic Ruthenium(III) Compound (KP418) with Hampered Transmembrane Transport in Electrochemotherapy In Vitro and In Vivo 175
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 173
Cytofluorimetric analysis of gut-intraepitelial and mesenteric lymph node lymphocytes of tumour bearing mice fed with egg-white lysozyme 173
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 173
Ruthenium complexes with high antitumoral and antimetastatic activities 172
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 172
Ruthenium dimeric compounds suitable as antimetastatic and antineoplastic agents 171
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 171
Preclinical combination therapy of the investigational drug NAMI-A with doxorubicin for mammary cancer 169
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition 168
Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients 168
In vitro cell cycle arrest, in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and of cisplatin. 167
Photolabile RuIIHalf-Sandwich Complexes Suitable for Developing “Caged” Compounds: Chemical Investigation and Unexpected Dinuclear Species with Bridging Diamine Ligands 165
Molecular structure, solution chemistry and biological properties of the novel [ImH][trans-IrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl(4)(DMSO)(2)], (II), complexes. 161
Novel water-soluble 99mTc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging 161
Ruthenium Anticancer Drugs 159
CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2 158
Synthesis, characterization and tumor cell growth inhibition of new transplatinum complexes with phosphane derivatives 156
Influence of Hydrogen-Bonding Substituents on the Cytotoxicity of RAPTA Compounds 155
Ruthenium(III) dimethyl sulfoxide pyridinehydroxamic acid complexes as potential antimetastatic agents: synthesis, characterisation and in vitro pharmacological evaluation 155
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferring. 152
DNA-adduct formation-guided design: thoughts about the future of metal based anticancer drugs 151
Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 150
Linking the future of anticancer metal complexes to the therapy of tumour metastases 150
Cytofluorimetric analysis of gut-intraepithelial and mesenteric lymph nodelymphocytes of tumour bearing mice fed with egg-white lysozyme. 148
Synthesis, characterization and biological activity of copper complexes with pyridoxal thiosemicarbazone derivatives. X-ray crystal structure of three dimeric complexes. 147
Synthesis and Chemical-Pharmacological Characterization of the Antimetastatic NAMI-A-Type Ru(III) Complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-Dimethyl [1,2,4]triazolo [1,5-a]pyrimidine) 147
Antimetastatic properties and DNA interactions of novel class of dimeric Ru(III) compounds Na2[trans-RuCl4(Me2SO)2(μ-L)] (L=ditopic, non chelating aromatic N-ligand). A preliminary investigation 147
Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity 146
Ruthenium-based compounds and tumour growth control (Review) 146
Biological Properties of Irim, the iridium(III) analogue of (imidazolium(bisimidazole)tetrachlororuthenate) (ICR) 146
Chitosan-coated alginate micro-particles delivery of active principles through conventional pelleted food - A study in Tilapia (Oreochromis niloticus) 144
Tumor cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells 143
In vitro cell cycle arrest,in vivo action on solid metastasizing tumors and host toxicity of the antimetastatic drug NAMI-A and cisplatin. 143
Reduction of in vivo lung metastases by dinuclear ruthenium complexes is coupled to inhibition of in vitro tumour invasion. 142
Hyperphosphorylation Maintenance Drives the Time-Course of G2-M Cell Cycle Arrest after Short Treatment with NAMI-A in KB Cells 142
New anionic and neutral complexes of Ru(III) with nitrogen oxide 141
Solution, solid state and biological characterization of ruthenium(III)-DMSO complexes with purine base derivatives. 141
Lysozyme stimulates lymphocyte response to ConA and IL-2 and potentiates 5-fluorouracil action on advanced carcinomas 138
PHARMACOLOGICAL APPROACHES TO SARS-CoV-2 INFECTION: FROM DRUG REPOSITIONING FOR COVID-19 TREATMENT TO DISEASE ARREST/PREVENTION WITH MoAbs AND NOVEL ANTIVIRALS 133
Lysozyme-induced transcriptional regulation of tnf-α pathway genes in cells of the monocyte lineage 133
Treatment of residual metastases with Na[trans-RuCl4(DMSO)Im) and ruthenium uptake by tumour cells 128
Antiviral properties and cytotoxic activity of platinum(II) complexes with 1,10-phenantrolines and acyclovir or penciclovir 128
Increase of tumour infiltrating lymphocytes in mice treated with antimetastatic doses of NAMI-A 127
Inhibition of endothelial cell functions and angiogenesis by the metastasis inhibitor NAMI-A 126
Modification of Lymphocytes of Peyer’s Patches-Mesentheric Lymphonodes Splean by Egg-White Lysozyme 125
CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after shot treatment with NAMI-A in KB cells 125
Tumour cell uptake, G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells 120
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin 117
The role of cisplatin and NAMI-A plasma-protein interactions in relation to combination therapy 116
Identification and measurement of transferrin receptors in a T-cell lymphocyte population by a fluorescent ligand 112
Totale 18.132
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.556
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.556
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.276 49 103 64 128 22 96 71 56 172 137 103 275
2022/20231.589 181 179 124 202 155 297 3 152 199 10 64 23
2023/2024938 84 55 33 52 95 57 114 305 9 15 48 71
2024/20252.674 18 150 483 187 204 286 160 149 299 256 197 285
2025/20265.937 434 404 529 573 499 539 893 206 626 790 238 206
2026/20277 7 0 0 0 0 0 0 0 0 0 0 0
Totale 20.376